The FDA has extended the review period for the BLA for NT-501 in the treatment of macular telangiectasia type 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback